Sysmex Inostics Expands Blood Test Offerings for Detection of Acute Myeloid Leukemia

Published on : Published by : BioBuzz Media

Sysmex Inostics, a global leader in the liquid biopsy revolution, has expanded its offering of CLIA-validated tests to include AML-SEQ™, a focused panel to detect mutations of the three most prevalent genes found in Acute Myeloid Leukemia (AML) – IDH1/2 & NPM1. 

QIAGEN forms strategic alliance with Sysmex Corporation for global cancer companion diagnostics development and commercialization using NGS and Plasma-Safe-SeqS technology

Published on : Published by : BioBuzz Media

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo Stock Exchange, First Section [Ticker Code: 6869]) for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).